SecurityGLPG / Galapagos N.V. (36315X101)
Institutional Owners84
Institutional Shares12,879,392
Institutional Value$ 889,327,000 USD

Institutional Stock Ownership and Shareholders()

GLPG / Galapagos N.V. Institutional Ownership

Galapagos N.V. (NASDAQ:GLPG) has 84 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 12,879,392 shares. Largest shareholders include Van Herk Investments B.v., Sands Capital Management, Llc, FMR LLC / Fidelity, Federated Investors Inc /pa/, Orbimed Advisors Llc, BlackRock Inc., Farallon Capital Management Llc, Baker Brothers Advisors LP, Wellington Management Group LLP, and Renaissance Technologies LLC.
Galapagos N.V. (NASDAQ:GLPG) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/glpg"><img src="https://images.fintel.io/us-glpg-so.png" alt="GLPG / Galapagos N.V. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-14 13F-HR Pacad Investment Ltd. 200 800 300.00 19 80 321.05
2018-05-15 13F-HR Rock Springs Capital Management LP 185,000 185,000 0.00 17,346 18,456 6.40
2018-05-15 13F-HR BARCLAYS PLC 16 93 481.25 2 9 350.00
2018-07-13 13F-HR ATRIA INVESTMENTS LLC 4,007 4,244 5.91 400 391 -2.25
2018-05-16 13F-HR Private Capital Group, Llc 1,220 94 -92.30 9 9 0.00
2018-02-14 13F-HR Belpointe Asset Management Llc 2,762 2,651 -4.02 281 249 -11.39
2018-05-14 13F-HR CASTLEARK MANAGEMENT LLC 6,770 6,704 -0.97 635 669 5.35
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 662 852 28.70 62 85 37.10
2018-05-15 13F-HR FARALLON CAPITAL MANAGEMENT LLC 290,000 308,260 6.30 27,190 30,752 13.10
2018-05-17 13F-HR/A EVENTIDE ASSET MANAGEMENT, LLC 52,000 40,000 -23.08 4,876 3,990 -18.17
2018-05-15 13F-HR Bank of New York Mellon Corp 39,446 39,609 0.41 3,698 3,951 6.84
2018-04-23 13F-HR Advisory Services Network, LLC 499 1,335 167.54 47 133 182.98
2018-05-11 13F-HR Cutler Group LP 500 800 60.00 46 79 71.74
2018-05-15 13F-HR Marshall Wace LLP 0 42,649 0 4,255
2018-05-01 13F-HR Unterberg Capital LLC 12,000 12,000 0.00 1,125 1,197 6.40
2018-05-14 13F-HR Hudson Bay Capital Management LP 0 13,700 0 1,367
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 1,488 332 -77.69 140 33 -76.43
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 18,837 5,927 -68.54 1,766 591 -66.53
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 0 12,500 0 1,247
2018-05-14 13F-HR ALLIANCEBERNSTEIN L.P. 38,050 38,050 0.00 3,568 3,796 6.39
2018-05-08 13F-HR US BANCORP \DE\ 2,501 1,716 -31.39 235 171 -27.23
2018-05-15 13F-HR PUTNAM INVESTMENTS LLC 20,912 2,086
2018-05-15 13F-HR Wellington Management Group LLP 268,326 253,128 -5.66 25,158 25,252 0.37
2017-02-15 SC 13G/A VAN HERK INVESTMENTS B.V. 3,423,363 3,943,150 15.18
2018-05-11 13F-HR Cutler Group LP Call 2,100 8,400 300.00 6 25 316.67
2018-05-09 13F-HR ENVESTNET ASSET MANAGEMENT INC 2,315 1,827 -21.08 217 182 -16.13
2018-05-01 13F-HR COOKSON PEIRCE & CO INC 4,060 4,160 2.46 381 415 8.92
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 5,205 5,205 0.00 519 480 -7.51
2018-05-15 13F-HR OLD MISSION CAPITAL LLC 26,225 2,616
2018-05-14 13F-HR ASCEND CAPITAL, LLC 0 25,063 0 2,501
2018-05-11 13F-HR CITIGROUP INC 355 47 -86.76 33 5 -84.85
2018-05-14 13F-HR FMR LLC / Fidelity 2,510,992 1,840,586 -26.70 235,431 183,617 -22.01
2018-05-04 13F-HR Financial Gravity Companies, Inc. 880 1,045 18.75 104 96 -7.69
2018-04-06 13F-HR Eqis Capital Management, Inc. 11,343 12,344 8.82 1,064 1,231 15.70
2018-05-14 13F-HR ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 38,952 0 -100.00 3,652 0 -100.00
2018-05-15 13F-HR JANE STREET GROUP, LLC 137,212 90,586 -33.98 12,865 9,037 -29.76
2018-05-11 13F-HR CITADEL ADVISORS LLC 3,566 356
2018-05-15 13F-HR DEUTSCHE BANK AG\ 72,120 81,847 13.49 6,760 8,163 20.75
2018-05-16 13F-HR Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp 70,000 70,000 0.00 6,563 6,983 6.40
2018-05-15 13F-HR Squarepoint Ops LLC 10,200 1,018
2018-02-15 13F-HR Bb&t Investment Services, Inc. 186 18
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 10,302 8,733 -15.23 967 871 -9.93
2018-05-14 13F-HR Renaissance Technologies LLC 235,200 227,100 -3.44 22,052 22,655 2.73
2018-05-03 13F-HR DekaBank Deutsche Girozentrale 6,350 636
2018-05-11 13F-HR Cutler Group LP Put 900 2,200 144.44 10 26 160.00
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 5,900 20,100 240.68 553 2,005 262.57
2018-05-15 13F-HR DAFNA Capital Management LLC 39,609 39,609 0.00 3,714 3,951 6.38
2018-05-15 13F-HR CLOUGH CAPITAL PARTNERS L P 66,453 49,953 -24.83 6,231 4,983 -20.03
2018-05-11 13F-HR MACQUARIE GROUP LTD 9,600 8,695 -9.43 900 867 -3.67
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 60 0 -100.00 6 0 -100.00
2018-05-09 13F-HR FEDERATED INVESTORS INC /PA/ 1,350,534 1,303,348 -3.49 126,626 130,022 2.68
2018-04-26 13F-HR SIMPLEX TRADING, LLC 98 0 -100.00 9 0 -100.00
2018-07-18 13F-HR REILLY FINANCIAL ADVISORS, LLC 3 0 -100.00 0 0
2018-05-15 13F-HR EcoR1 Capital, LLC 110,384 0 -100.00 10,350 0 -100.00
2018-05-10 13F-HR Stratos Wealth Partners, LTD. 350 35
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 45,404 34,576 -23.85 4,257 3,449 -18.98
2018-05-01 13F-HR COMERICA BANK 2,730 2,766 1.32 312 271 -13.14
2018-04-26 13F-HR P.A.W. CAPITAL CORP 12,000 9,000 -25.00 1,125 898 -20.18
2017-08-08 13F-HR Airain ltd 2,749 12,204 343.94 237 934 294.09
2018-04-18 13F-HR/A FNY Partners Fund LP 20,200 0 -100.00 1,893 0 -100.00
2018-05-09 13F-HR BlackRock Inc. 346,802 324,820 -6.34 32,516 32,405 -0.34
2018-05-15 13F-HR Jefferies Group LLC 10,745 0 -100.00 1,007 0 -100.00
2018-05-14 13F-HR Virtu Financial LLC 4,282 427
2018-05-02 13F-HR Daiwa Securities Group Inc. 60 6
2018-05-11 13F-HR LANDSCAPE CAPITAL MANAGEMENT, L.L.C. 4,141 13,895 235.55 388 1,386 257.22
2018-05-14 13F-HR Tekla Capital Management LLC 53,200 95,635 79.77 4,988 9,541 91.28
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 5,938 5,938 0.00 556 592 6.47
2018-05-15 13F-HR CREDIT SUISSE AG/ 95,195 182,369 91.57 8,926 18,194 103.83
2018-07-18 13F-HR World Asset Management Inc 2,019 0 -100.00 201 0 -100.00
2018-05-15 13F-HR Advisor Group, Inc. 3,492 3,580 2.52 327 357 9.17
2018-05-04 13F-HR VICTORY CAPITAL MANAGEMENT INC 18,296 20,356 11.26 1,715 2,031 18.43
2018-05-15 13F-HR UBS Group AG 1,597 1,202 -24.73 150 120 -20.00
2018-05-15 13F-HR We Are One Seven, Llc 151 15
2018-05-14 13F-HR ProShare Advisors LLC 5,875 4,964 -15.51 551 495 -10.16
2018-05-15 13F-HR Atika Capital Management LLC 15,500 18,000 16.13 1,453 1,796 23.61
2018-05-08 13F-HR Aperio Group, LLC 7,603 9,300 22.32 713 928 30.15
2018-02-14 13F-HR GLG Partners LP 0 2,979 0 279
2018-07-18 13F-HR Bedel Financial Consulting, Inc. 25 25 0.00 2 2 0.00
2017-02-15 13F-HR OLD MISSION CAPITAL, LLC 11,391 731
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 2,870 3,566 24.25 269 356 32.34
2018-05-15 13F-HR ORBIMED ADVISORS LLC 486,990 486,990 0.00 45,660 48,582 6.40
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 8,793 0 -100.00 569 0 -100.00
2018-05-15 13F-HR Williams Jones & Associates LLC 6,645 6,645 0.00 623 663 6.42
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 116,616 10,710 -90.82 10,934 1,068 -90.23
2018-05-14 13F-HR MORGAN STANLEY 84,133 56,330 -33.05 7,888 5,619 -28.77
2018-07-12 13F-HR PEREGRINE CAPITAL MANAGEMENT LLC 102,136 107,675 5.42 10,189 9,925 -2.59
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 81 949 1,071.60 8 95 1,087.50
2018-05-15 13F-HR PERCEPTIVE ADVISORS LLC 206,305 206,305 0.00 19,343 20,581 6.40
2018-05-10 13F-HR JP Morgan Chase & Co 26,718 0 -100.00 2,505 0 -100.00
2018-05-11 13F-HR Quantbot Technologies LP 766 1,145 49.48 71 114 60.56
2018-05-10 13F-HR Employees Retirement System of Texas 54,000 56,000 3.70 5,063 5,587 10.35
2018-05-15 13F-HR PEAK6 Investments, L.P. Call 5,300 0 -100.00 497 0 -100.00
2018-05-15 13F-HR SANDS CAPITAL MANAGEMENT, LLC 1,998,311 1,878,686 -5.99 187,362 187,418 0.03
2018-05-15 13F-HR DEERFIELD MANAGEMENT CO 130,000 130,000 0.00 12,189 12,969 6.40
2018-05-01 13F-HR ALPS ADVISORS INC 56,310 68,155 21.04 5,280 6,799 28.77
2018-05-23 13F-HR Financial Gravity Wealth, Inc. 1,045 96
2018-05-14 13F-HR Qube Research & Technologies Ltd 1,830 182
2017-10-26 13F-HR Acrospire Investment Management LLC 7 0 -100.00 1 0 -100.00
2018-07-05 13F-HR Dorsey Wright & Associates 90,358 98,544 9.06 8,733 9,312 6.63
2018-05-15 13F-HR HBK INVESTMENTS L P 2,987 8,399 181.19 280 838 199.29
2018-05-15 13F-HR Baker Brothers Advisors LP 259,894 259,894 0.00 24,368 25,927 6.40
2018-05-15 13F-HR UBS Group AG Call 1,400 0 -100.00 131 0 -100.00

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish

2018-07-11 seekingalpha
Note: ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is when we covered it. (53-3)

Gilead Q2 Results Could Initiate A Rally

2018-07-09 seekingalpha
Last winter I wrote the glum, only somewhat tongue-in-cheek, Gilead Sciences: Going Down When It Should Go Up. The day before it was published, Gilead Sciences (NASDAQ:GILD) closed at $72.70. On July 6, 2018, it closed at $75.21, but it has been as low as $64.27 in the interim. Gilead seems to have become the Rodney Dangerfield of large biotech companies: it don't get no respect, despite its enormous revenues and profits. (6-2)

Galectin Therapeutics IPF Patent Solidifies Platform Technology Status

2018-07-05 seekingalpha
Galectin Therapeutics (NASDAQ:GALT) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA:IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise of a key departing officer continued to weigh on the price. Based on the recent Form 4 Filings, the selling pressure has abated because the officers have simply run out of options to sell. (24-0)

Galapagos: Highly Enriched Pipeline And Strong Growth Prospects

2018-06-29 seekingalpha
Galapagos is powering an extremely enriched and robust therapeutic pipeline of many potential blockbusters. Despite the strong prospects of various molecules, we are most interested in the JAK1 inhibitor (filgotinib). (13-2)

FibroGen: Strong Fundamentals, Solid Long-Term Prospects

2018-06-04 seekingalpha
What strikes a first-time investor in FibroGen, Inc. (NASDAQ:FGEN) is that despite having no product in the market, this company is already valued at above $4bn and has a cash balance of almost $800mn in its coffers. That tells us that the company is doing something right, or at least that the market thinks so. (9-2)

CUSIP: 36315X101